Impact of informative censoring on estimation and testing in randomized trials with delayed treatment effects

被引:0
作者
Lin, Jingyi [1 ,3 ]
Zhao, Yujie [1 ]
Chen, X. Gregory [2 ]
Donica, Margarita [2 ]
Leon, Larry
Trinquart, Ludovic [3 ,4 ,5 ]
Wan, Shuyan Sabrina [1 ]
机构
[1] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ 07065 USA
[2] MSD Innovat & Dev GmbH, Biostat & Res Decis Sci, Zurich, Switzerland
[3] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
[4] Tufts Univ, Tufts Clin & Translat Sci Inst, Boston, MA USA
[5] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA
关键词
Informative censoring; Randomized clinical trial; Coupla; Nonproportional hazard ratio; Survival analysis; PROGRESSION-FREE SURVIVAL; INVERSE-PROBABILITY; RANK; NONCOMPLIANCE; SENSITIVITY; ASSUMPTION; TIME;
D O I
10.1016/j.cct.2025.107860
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Time-to-event endpoints like progression-free survival in oncology randomized trials sometimes demonstrate differential censoring patterns between study arms which can be indicative of informative censoring, depending on censoring reasons. Informative censoring can bias treatment effect estimates but few simulation studies characterized the magnitude of its impact, particularly in the context of therapies with delayed treatment effects. We used copula methods to model dependent censoring data and assessed the impact of informative censoring. To improve the understanding of copula models in this context, we proposed a new measure of the strength of informative censoring, the probability of events being informatively censored. We further proposed a visual tool for examining the underlying correlation pattern between censoring and event time. We conducted simulation studies to assess the impact of informative censoring on estimation bias for hazard ratios, as well as on empirical power of unweighted, weighted log-rank tests, and the MaxCombo test. We implemented data generation algorithm for copula survival models with piece-wise exponential marginals to introduce various censoring patterns under scenarios with delayed treatment effect. We found large overestimation of hazard ratio of the experimental arm versus the control arm and loss in power when there was a positive correlation between event time and censoring time in the control arm and a negative correlation in the experimental arm. When correlations in both arms were of the same direction and degree, we observed minimal impact on hazard ratio estimate and statistical powers.
引用
收藏
页数:10
相关论文
共 34 条
[21]   Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints [J].
Lipkovich, Ilya ;
Ratitch, Bohdana ;
O'Kelly, Michael .
PHARMACEUTICAL STATISTICS, 2016, 15 (03) :216-229
[22]   ASYMPTOTICALLY EFFICIENT RANK INVARIANT TEST PROCEDURES [J].
PETO, R ;
PETO, J .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1972, 135 :185-&
[23]   Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests [J].
Robins, JM ;
Finkelstein, DM .
BIOMETRICS, 2000, 56 (03) :779-788
[24]   Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing [J].
Rosen, Kate ;
Prasad, Vinay ;
Chen, Emerson Y. .
EUROPEAN JOURNAL OF CANCER, 2020, 141 :152-161
[25]   Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].
Rugo, Hope S. ;
Bardia, Aditya ;
Marme, Frederik ;
Cortes, Javier ;
Schmid, Peter ;
Loirat, Delphine ;
Tredan, Olivier ;
Ciruelos, Eva ;
Dalenc, Florence ;
Pardo, Patricia Gomez ;
Jhaveri, Komal L. ;
Delaney, Rosemary ;
Fu, Olivia ;
Lin, Lanjia ;
Verret, Wendy ;
Tolaney, Sara M. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) :3365-+
[26]   The Kaplan-Meier estimator as an inverse-probability-of-censoring weighted average [J].
Satten, GA ;
Datta, S .
AMERICAN STATISTICIAN, 2001, 55 (03) :207-210
[27]   Impact of unequal censoring and insufficient follow-up on comparing survival outcomes: Applications to clinical studies [J].
Srivastava, Deo Kumar ;
George, E. Olusegun ;
Lu, Zhaohua ;
Rai, Shesh N. .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2021, 30 (09) :2057-2074
[28]   Exaggeration of PFS by blinded, independent, central review (BICR) [J].
Stone, A. ;
Gebski, V. ;
Davidson, R. ;
Bloomfield, R. ;
Bartlett, J. W. ;
Sabin, A. .
ANNALS OF ONCOLOGY, 2019, 30 (02) :332-338
[29]  
TSIATIS A, 1975, P NATL ACAD SCI USA, V72, P20, DOI 10.1073/pnas.72.1.20
[30]   A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards [J].
Wang, Lili ;
Luo, Xiaodong ;
Zheng, Cheng .
PHARMACEUTICAL STATISTICS, 2021, 20 (04) :879-897